Introduction
Within the last 40 years, the field of antiviral therapy has grown from the development of the first clinically available compound to the current, ever expanding list of antiviral agents. This growth is the result of directed research programmes, which have flourished with the development of viral assay systems, and our increased understanding of viral replication. The products of these research programmes now mean that safe and effective treatments are available for a range of diseases from the mild to the chronically debilitating. With continued research, the list of treatable viral infections should continue to expand.
Historical perspective
The development of antiviral agents has been a much slower process than that of antibacterial compounds. Antibacterial agents were in clinical use in the 1930s, and many diverse agents have since been developed. In contrast, the first antivirals were discovered in the 1950s, and did not come into clinical use until the 1960s. Since the 1980s there has been a marked acceleration in the development of antiviral compounds. However, there are still relatively few antiviral agents in clinical use and these are effective in only a limited number of indications (Table 1) .
There were two main reasons for the slow development of antiviral compounds. Firstly, the lack of knowledge concerning the virus life-cycle, coupled with the fact that viruses are obligate intracellular parasites, led to concerns that agents toxic to the virus would also prove toxic to the host cell. This expectation was borne out by some of the early antiviral compounds which were associated with significant toxicity. However, subsequent molecular research into the mechanisms of viral replication has revealed numerous processes that are specific to the virus. Many of these processes provide potential target sites for antiviral agents, for example, absorption of the virus into the host cell, replication of the viral genome, synthesis and translation of the viral RNA, and assembly and release of virus particles. This information has facilitated the development of antiviral agents.
The second problem was the absence of systems for testing compounds for antiviral activity. Without a reliable and reproducible system for assaying viral growth, the possible inhibitory effects of compounds could not be examined. This was overcome by the development of assay systems, first in eggs, then in mice, and finally in tissue culture systems. Most screening for antiviral agents is now carried out using cell culture systems. However, for some viruses simple culture systems are not yet available, while others such as human immunodefrciency virus (HIV) require elaborate containment facilities, which restricts screening procedures. Compounds showing antiviral activity in these screening systems can then be further developed for testing in humans.
The first virus assay system was developed by Brownlee & Hamre (1951) . This assay involved injecting virus into fertilized egg yolk sacs. The survival time of the embryos was found to be inversely proportional to the dose of vaccinia virus injected into eggs on the sixth day of incubation. Compounds were tested for antiviral activity by injecting them into eggs which had been infected with the vaccinia virus. Their effects on embryo survival were then 6 measured. Increases in embryo survival time indicated antiviral activity.
The development of this assay system marked an important stage in the history of antiviral agents, since a system was now available in which closely related compounds could be tested and compared. Thus, the effects of modifications in the structure of the compounds could be measured, and a series of related compounds could be produced and tested in this system to determine the most potent agent; structureactivity relationships could therefore be studied.
The development of tissue culture systems further promoted the search for new antiviral agents. The early tissue culture systems were only qualitative and were still very labour intensive. These were gradually refined, with the introduction of the plaque inhibition assay in 1960, which provided an easier quantitative screening system for large numbers of compounds. The development of modern tissue culture techniques reduced the workload and allowed large numbers of compounds to be tested in different cell types.
The frrst set of compounds tested in the egg yolk assay system were the sulphonamides, which were originally developed as antibacterial agents. These tests revealed that methisazone (para-benzaldehyde thiosemicarbazone) was effective against vaccinia virus infection, producing the equivalent of a 70% reduction in the infecting dose of the virus (Hamre et al., 1950) .
In 1962, methisazone was successfully used to treat a 7-month-old boy with eczema vaccinatum. The infant had contracted vaccinia from his vaccinated mother and had extensive lesions on the scalp, face and limbs with pyrexia, ? prostration and toxaemia. Previous treatment with antivaccinia virus gamma-globulin had been ineffective. This was probably the first clinical use of an antiviral agent (Turner et al., 1962) .
Methisazone was subsequently used to treat other cases of eczema vaccinatum and later the more serious infective complication ofvaccinia, vaccinia gangrenosa. Methisazone was found to be equally effective against both conditions.
Methisazone was later tested as a prophylatic agent against smallpox (Bauer et al., 1969) . In a trial involving nearly 5500 patients, less than 1% of methisazone-treated patients developed smallpox within 16 days of contact with the virus, compared with over 4% of the control group. The prophylactic treatment also produced a similar reduction in mortality. The discovery of an antiviral agent which could effectively prevent smallpox was a major achievement at the time. Fortunately, with the eradication of smallpox, this therapy is no longer needed.
Another important milestone in the development of antiviral treatment came with a demonstration that amantidine given prophylactically could prevent influenza. The antiviral activity of this agent was initially demonstrated in mice and egg yolk systems (Davies et al., 1964) . Activity against rubella was also observed in the egg yolk system but did not translate into effective antiviral activity in animal models. In a clinical trial carried out by Jackson and coworkers (Jackson et al., 1963) , 200 volunteers lacking the influenza antibody were infected with the Asian strain of the virus. Only 37% of the amantidine-treated group, compared with 66% of the placebo-treated group (P<O.Ol), became infected, thus demonstrating a prophylactic activity for amantidine. TIllS finding was confirmed in a study by Couch (1990) involving family contacts of patients with influenza. Daily prophylactic administration of amantidine over 2-3 months during the influenza outbreak showed 70% efficacy in preventing infection. Despite its proven efficacy,amantidine is not used widely. A derivative of amantidine, rimantidine, has been developed which has a more favourable side-effect profile, but this too is not widely used.
Another of the early antiviral agents is ribavirin, a nucleoside analogue with activity against a wide range of DNA and RNA viruses. Ribavirin was developed in the 1970s and found to have a wide spectrum of activity but its use was limited by the need to administer it by aerosol. This agent is active against several serious viral infections, for example, Lassa fever.
Early antiherpes agents
The 1960s signalled the start of an acceleration in the number of antiviral compounds being developed. New antiviral agents were derived both from existing com-
Antiviral therapy pounds and from research into new types of molecules, such as synthetic nucleosides. This decade also saw the start of directed research programmes, in which research was targeted at a specific virus type. The first of these research programmes aimed to develop antiherpes compounds and proved to be one of the most successful' areas of progress in antiviral therapy.
The first antiherpes agent to be identified in this programme was idoxuridine (IDU), a synthetic nucleoside previously shown to have antineoplastic activity. Kaufman demonstrated its efficacy in herpetic keratitis models, first in rabbits, and then in humans (Kaufman et al., 1964) . This lead to the introduction of IDU as a topical agent. Intravenous administration ofIDU was investigated for the treatment of patients with herpes encephalitis but was stopped due to unacceptable toxicity and lack of efficacy. Cytarabine, another compound which was effective in tissue culture experiments against both herpes simplex virus (HSV) and varicella zoster virus (VZV) (Rapp, 1964) , proved to be highly toxic and of dubious clinical efficacy as an antiviral agent. Trifluorothymidine (TFT) was among the most successful of the these early antiherpes agents, again showing activity in the rabbit herpetic keratitis model. In a clinical trial in 78 patients with herpetic keratitis, Wellings et ai. (1972) showed that healing occurred in 92.5% of TFTtreated patients, compared with 60.5% of the IDU-treated group, and that mean healing time was reduced by 2 days for TFT-treated patients. Thus, TFT became the standard treatment for herpetic keratitis. TFT is only suitable as a topical agent. This makes it unsuitable for use against other conditions caused by herpes simplex virus.
Vidarabine was also developed around the same time and was the first clinical antiviral agent to be used intravenously. Schabel and colleagues showed that it was active against both cytomegalovirus (CMV) and VZV (Schabel, 1968) , but it also showed activity against HSV. In one study in patients with HSV encephalitis (Whitley et al., 1977) , vidarabine reduced mortality from 70% for placebo to 28%, and those patients who received vidarabine early in the course of encephalitis had fewer neurological sequelae. Vidarabine thus became the treatment of choice in herpes encephalitis.
Acyclic nucleoside analogues
It was the development of acyclic nucleoside analogues that marked the major step forward in the treatment of herpesvirus infection. Among the first of these, aciclovir, was found to be 10 times more active than IDU and 600 times more active than vidarabine, making it the most potent antiherpes agent available when it was introduced. Aciclovir is effective against acute and recurrent genital herpes and the acute symptoms of herpes zoster (McKendrick et al., 1986) .
Thus, it became standard therapy for these herpes infections. However, the poor oral bioavailability (10-20%) of aciclovir necessitates frequent dosing and may compromise efficacy under some conditions. Bioavailability problems have been overcome to a large degree by the recent introduction of an aciclovir prodrug, valaciclovir, and the prodrug famciclovir, which is converted in the body to penciclovir. These prodrugs have ester groups linked to the parent molecule which facilitate absorption, thus giving higher bioavailability of the respective nucleosides. The conversion of both famciclovir and valaciclovir into their respective nucleosides occurs in the liver. Both prodrugs are absorbed into the blood from the gastrointestinal tract and pass into the portal system. In the liver they are metabolized to their active forms, which then pass into the general circulation (Perry & Wagstaff, 1995; Perry & Faulds, 1996) .
Studies show that valaciclovir increases the systemic bioavailability of aciclovir to 54%, and famciclovir provides even higher levels of the active agent, penciclovir, with bioavailability of 77% (Perry & Wagstaff, 1995; Perry & Faulds, 1996) .
Prodrugs have the advantage that their pharmacokinetics are largely predictable and consistent. This allows physicians to predict the plasma levels of the active molecule produced by different doses of the prodrug. This dose proportionality can be seen in the plasma levels of penciclovir for different doses of famciclovir (Pue & Benet, 1993) .
Intracellular action of penciclovir and aciclovir
Penciclovir and aciclovir inhibit viral replication by broad-ly similar mechanisms (Fig. 1 ). Aciclovir and penciclovir diffuse freely across the plasma membrane into cells. If the cells are uninfected, the drugs move in and out of the cell unchanged. In cells infected with a herpesvirus, however, penciclovir and aciclovir are phosphorylated by the viral thymidine kinase enzyme to the monophosphate form which is subsequently converted to the triphosphate form by cellular enzymes. These triphosphates are the active antiviral molecules which block viral DNA synthesis by competing with the natural nucleotides for the viral DNA polymerase.
A difference between penciclovir and aciclovir lies in the behaviour of the triphosphate form of the molecule. Intracellular aciclovir triphosphate is much less stable than penciclovir triphosphate, so it is readily converted back into aciclovir, which can easily diffuse out of the cell. Thus the half-life of aciclovir triphosphate in infected cells is only about 1 h. In contrast, penciclovir triphosphate is much more stable. In cells infected with HSV it has a half-life of 10-20 h and in VZV-infected cells, its half-life is about 9 h (Fig. 2) (Bacon etal., 1996) . This means that famciclovir can potentially be given less frequently than aciclovir.
Clinical efficacy
Aciclovir, valaciclovir and famciclovir have all been studied in various clinical settings involving herpesvirus infection (Perry & Wagstaff, 1995; Perry & Faulds, 1996) . Articles in this supplement discuss the clinical uses of these antiherpes agents in patients with herpes zoster, herpes labialis and genital herpes. The clinical advantages of these prodrugs, particularly famciclovir, relative to aciclovir are also discussed. (1993) and Bacon et al. (1996) .
Future challenges for antiviral research References
These antiherpes agents are only a few of the antiviral agents that have been developed in the last 10-20 years.
Other antiviral agents currently in development or in clinical use include acyclic nucleoside phosphonates (such as adefovirand cidofovir) (De Clercq, 1995) pyrimidine nucleoside analogues (for example brivudine and netivudine) (De Clercq, 1995) and dideoxynucleoside analogues, which have formed the basis of most HIV treatment. An entirely new class of antiviral agents, the protease inhibitors, has also appeared recently. This range of compounds, together with the acyclic nucleoside analogues discussed earlier, allows the physician to treat a wide range ofvirus infections, including HSV-1, HSV-2, CMV, VZv, Epstein-Barr virus, and human herpesvirus 6, 7 and 8. However, despite the recent advances in antiviral treatments, numerous challenges lie ahead. Effective treatments for certain viral infections, such as HIV and CMV, still need to be found. We still need to address the problems oflatency, and whether the cycle oflatency and reactivation can be interrupted. This issue is addressed in an article included in this supplement by Field & Thackray, (pp. 59-66). The development of therapeutic vaccines for herpes simplex, and possibly herpes zoster, is another area of active research. The need for earlier, more accurate diagnoses of viral diseases and the possibilities of co-therapy for viral infections such as hepatitis B are other challenges to be addressed. Finally, there are the possibilities for treatment offered by gene therapy and by expression vectors carrying antiviral agents.
